Advanced Biotherapy (fka ADVB)

[Steveg]

insidestraight: I plead puzzlement. How many shareholders are you referring to?

The vast number of outstanding shares is another issue. You may already know the story. Last year the company had approximately 52 million shares outstanding. The company was restructured, and the major creditor, Richard Kiphart, received shares in lieu of funds priced at .015. That, and distributions to others to whom the company was indebted, ramped up the number of shares. The rights offering, in which the dollar and dime shareholders can acquire 10 shares for every 1 share owned (also at .015), should put those shareholders in the same relative position they were before the dilution that occurred at the time of company restructuring last August.

Steve